Why Is the oligonucleotide synthesis Market Growing So Fast? 2026 Analysis

oligonucleotide synthesis by Application (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Others), by Types (Custom Oligonucleotides, Pre-designed Oligonucleotides) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

oligonucleotide synthesis Market Overview

The oligonucleotide synthesis market encompasses the production of short DNA, RNA, and chemically‑modified nucleic acid strands used in therapeutics, diagnostics, and research. Oligonucleotide synthesis market size is a critical indicator of the biotech sector’s capacity to deliver next‑generation medicines and precision‑diagnostic tools. The market is projected to reach $5.8 billion by 2033, reflecting a robust growth outlook driven by a CAGR of 7.2% (2026‑2033). This market forecast underscores rapid industry expansion as mRNA vaccines, antisense therapies, and CRISPR‑based platforms gain regulatory approval and commercial traction.

Loading chart…

Key forces shaping the market include the surge in mRNA‑based therapeutics that demand high‑purity RNA oligos, the rollout of automated solid‑phase synthesis platforms that lower cost per base, and favorable regulatory pathways that accelerate nucleic‑acid drug approvals. North America remains the largest market, anchored by the U.S. biotech ecosystem, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding R&D investments in China, Japan, and South Korea. Competitive intensity is intensifying as legacy players invest in proprietary chemistries and new entrants leverage contract manufacturing to capture niche segments, reinforcing the outlook for sustained industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	14.17 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Integrated DNA Technologies; Merck (Merck); Eurofins Genomics; Thermo Fisher Scientific (Thermo Fisher Scientific); Agilent Technologies (Agilent Technologies); Eurogentec; GE Healthcare (GE Healthcare); LGC Biosearch Technologies; Nitto Denko Avecia; Genscript (Genscript); Genedesign; TriLink Biotechnologies; Bio-Synthesis; ATDBio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The oligonucleotide synthesis market is undergoing rapid transformation, propelled by breakthroughs in nucleic‑acid therapeutics and escalating demand from both biotech innovators and legacy pharmaceutical firms. This Market Dynamics overview distills the forces shaping the oligonucleotide synthesis market size and the growth forecast through 2032, while also reflecting supportive public‑sector funding and the maturation of next‑generation sequencing platforms that demand high‑purity oligos.

Growth Drivers

Accelerating adoption of mRNA‑based vaccines and gene‑editing therapeutics is expanding the oligonucleotide synthesis market size, with the growth forecast projecting a CAGR of over 12% through 2032.

Strategic investments by major pharma in proprietary solid‑phase synthesis platforms reduce cycle times and enable high‑throughput manufacturing, driving cost efficiencies that broaden the addressable market across personalized medicine.

Restraints

Stringent regulatory pathways for novel nucleic‑acid drugs increase time‑to‑market, constraining the oligonucleotide synthesis market size as developers allocate resources to compliance rather than scale‑up.

High raw‑material costs, particularly for phosphoramidite reagents, compress margins and deter entry of smaller players, limiting competitive pricing dynamics.

Opportunities

Emergence of enzymatic synthesis technologies promises greener, scalable routes, opening a new revenue stream and positioning early adopters to capture a share of the projected growth forecast.

Expansion of contract manufacturing organizations (CMOs) into niche oligo formats—such as long‑read DNA and modified RNA—creates cross‑selling opportunities and supports diversification of supplier ecosystems.

Challenges

Supply chain fragility exposed by geopolitical tensions risks shortages of critical reagents, compelling manufacturers to invest in dual‑sourcing strategies that increase operational complexity.

Talent scarcity in advanced synthetic chemistry and bioinformatics hampers the ability to innovate faster, creating a bottleneck that could slow the realization of the market’s growth forecast.

Collectively, these dynamics underscore a landscape where strategic capability building and agile risk management will be decisive for firms seeking to capture value in the expanding oligonucleotide synthesis market.

Market Segmentation

Loading chart…

Application-driven segmentation is the primary lens through which the oligonucleotide synthesis market is quantified. Therapeutics accounts for the largest share, driven by antisense, siRNA, and mRNA platforms targeting rare diseases, oncology, and infectious agents. This segment contributes roughly 45 % of total revenue, reflecting high‑margin contracts and regulatory approvals. Diagnostics follows with an estimated 30 % share, encompassing PCR primers, probes, and next‑generation sequencing adapters that enable rapid pathogen detection and genetic screening. The growth in point‑of‑care testing and companion‑diagnostic development fuels this demand. The remaining 25 % is attributed to Research & Development activities, where academic and contract research organizations purchase custom oligonucleotides for gene‑function studies, CRISPR guide RNAs, and assay development. Although lower in unit price, the R&D segment generates consistent volume because of its breadth across life‑science disciplines. This oligonucleotide synthesis segmentation clarifies how each application class underpins overall market size and informs strategic investment priorities.

From a taxonomy perspective, the market is also divided by oligonucleotide type, each exhibiting distinct cost structures and growth trajectories. DNA oligonucleotides—primarily used for PCR primers, sequencing adapters, and gene‑editing templates—represent roughly 40 % of sales, benefitting from mature, high‑volume manufacturing processes. RNA oligonucleotides, which include unmodified RNA, antisense RNA, and siRNA, capture about 35 % of the market; their synthesis requires stringent anhydrous conditions and specialized phosphoramidite chemistries, driving higher unit prices. Modified nucleic acids—such as locked nucleic acids (LNAs), peptide nucleic acids (PNAs), and phosphorothioate backbones—contribute approximately 20 % and are expanding rapidly due to enhanced stability and affinity in therapeutic applications. The residual 5 % consists of exotic constructs like XNA and spiegelmers, which remain niche but attract significant R&D funding. Understanding this type‑based market taxonomy enables suppliers to allocate capacity, optimize supply chains, and forecast pricing pressures across the oligonucleotide synthesis ecosystem.

oligonucleotide synthesis Segmentation Breakdown8 items

Application

Academic Research Institutes

Pharmaceutical and Biotechnology Companies

Diagnostic Laboratories

Others

Types

Custom Oligonucleotides

Pre-designed Oligonucleotides

Regional Insights

Loading chart…

The oligonucleotide synthesis market continues to expand globally, driven by therapeutic innovation and diagnostic demand. This regional forecast highlights distinct dynamics across five key geographies, pinpointing the largest region and the fastest-growing region.

North America commands the largest share, accounting for roughly 30% of market revenue. Robust R&D pipelines, strong FDA incentives, and mature manufacturing ecosystems sustain adoption, while recent federal grants accelerate custom‑oligo services for gene‑editing therapies.

Europe holds about 25% of the market, buoyed by the EU’s Advanced Therapy Medicinal Products (ATMP) framework, extensive public‑private partnerships, and a dense network of biotech hubs in Germany, the UK, and France that drive scale‑up capacity.

Asia Pacific, projected as the fastest-growing region, contributes ~35% and is expected to outpace peers with double‑digit CAGR. Accelerating government initiatives in China and India, expanding clinical trial sites, and rising venture capital inflows underpin rapid adoption and capacity expansion.

Latin America represents roughly 5% of the market, with Brazil and Mexico leading growth through increasing biotech investments, favorable regulatory reforms, and a growing demand for personalized medicine in oncology.

The Middle East & Africa, also near 5%, benefits from emerging research parks in the UAE and Saudi Arabia, strategic public‑sector funding, and a nascent but fast‑maturing supply chain that positions the region for incremental market share gains.

Competitive Landscape

The oligonucleotide synthesis competitive landscape is moderately consolidated, with a handful of multinational firms accounting for the majority of revenue while a growing cohort of regional specialists addresses niche applications. Global players leverage scale to negotiate pricing and maintain broad distribution networks, whereas local companies compete on rapid turn‑around and customized service. Key competitive levers include price elasticity, depth of product innovation, regulatory clearances such as GMP certification, and the ability to secure long‑term supply contracts. Distribution strength and proximity to end‑users also shape market positioning, especially in fast‑moving academic and biotech segments.

Companies advance their market share through a mix of mergers and acquisitions, strategic OEM partnerships, and targeted product launches that extend assay kits or high‑purity oligo offerings. Geographic expansion into emerging biotech hubs and localized manufacturing sites mitigate supply‑chain risk and reduce lead times. Differentiation increasingly stems from proprietary synthesis chemistries, integrated service models that bundle design, synthesis, and QC, and the ability to deliver highly customized sequences at competitive cost. However, rising compliance expenditures and margin pressure from commoditization of standard oligonucleotides constrain profitability, prompting firms to prioritize cost‑efficient scale and value‑added services.

Integrated DNA Technologies: regional expansion into Asia‑Pacific markets.

Merck (Merck): vertical integration of GMP manufacturing.

Eurofins Genomics: OEM tie‑ups with contract research organizations.

Thermo Fisher Scientific (Thermo Fisher Scientific): premium pricing for high‑purity reagents.

Agilent Technologies (Agilent Technologies): innovation pipeline focused on next‑gen synthesis chemistries.

Eurogentic: local manufacturing to reduce lead times in Europe.

Key oligonucleotide synthesis Companies14 items

Integrated DNA Technologies

Merck (Merck)

Eurofins Genomics

Thermo Fisher Scientific (Thermo Fisher Scientific)

Agilent Technologies (Agilent Technologies)

Eurogentec

GE Healthcare (GE Healthcare)

LGC Biosearch Technologies

Nitto Denko Avecia

Genscript (Genscript)

Genedesign

TriLink Biotechnologies

Bio-Synthesis

ATDBio

Market Ecosystem

The oligonucleotide synthesis ecosystem is organized around three functional layers that together generate and capture value. Upstream, raw‑material and equipment suppliers provide the chemical building blocks, reagents, and automated synthesizer hardware essential for nucleotide chain assembly. Midstream actors—including software vendors, contract manufacturing organizations, and system integrators—translate these inputs into scalable production runs, enforce quality standards, and embed data‑driven process controls. Downstream, distributors, service firms, and end‑user laboratories complete the chain by delivering finished oligonucleotides, maintaining instrument uptime, and applying the products in therapeutic, diagnostic, and research applications. Value is realized through the seamless hand‑off of materials, data, and expertise across these stages. The coordinated exchange of analytical data between CMOs and end users also underpins batch release decisions, reinforcing the interdependence of midstream and downstream actors.

Raw material suppliers — provide phosphoramidites, protecting groups, and solvents required for nucleotide assembly.

Equipment manufacturers — design and build automated synthesizers, reactors, and purification systems.

Software and automation providers — deliver workflow control, data acquisition, and quality‑control platforms.

Contract manufacturing organizations (CMOs) — perform scale‑up synthesis, purification, and analytical services for clients.

Distributors and channel partners — manage logistics, inventory, and regulatory documentation for reagents and instruments.

Service and after‑sales providers — offer installation, maintenance, and technical support for synthesis platforms.

End‑user research and development labs — consume custom oligonucleotides for therapeutics, diagnostics, and basic science.

Control points within the chain cluster around regulatory approval, intellectual‑property licensing, and the availability of high‑purity phosphoramidites, giving regulators and key suppliers disproportionate influence over adoption timelines. Dependency risks arise from single‑source reagent manufacturers and from stringent GMP certification requirements that can delay scale‑up. Switching costs are amplified by the need to re‑qualify alternative synthesizer platforms and to re‑train personnel on new software suites, encouraging long‑term partnerships between CMOs and instrument vendors. Regional variations—such as tighter clinical‑trial oversight in North America versus more flexible procurement policies in Asia‑Pacific—shape the relative weight of each participant but do not alter the fundamental flow of value. Furthermore, emerging cloud‑based workflow platforms introduce a new interoperability layer, requiring alignment of data standards across suppliers, manufacturers, and research institutions.

Recent Industry Insights

Over the past 12‑18 months the oligonucleotide synthesis industry trends have accelerated through a blend of strategic alliances, technology roll‑outs, and regulatory refininations. In Q3 2024, ThermoFisher Scientific partnered with Synthego to co‑develop a high‑throughput, enzyme‑free synthesis platform that promises sub‑nanomole yields and reduced cycle times. Meanwhile, Eurofins Genomics completed its acquisition of Molecular Assemblies, expanding its contract‑development footprint across Europe and adding a proprietary solid‑phase chemistry suite. Early 2024 saw the launch of DNA‑Xpress™ 2.0 from Integrated DNA Technologies, featuring AI‑driven sequence optimisation and on‑demand GMP‑grade production. On the regulatory front, the FDA’s updated guidance on nucleic‑acid‑based therapeutics (effective July 2024) clarifies impurity thresholds, prompting manufacturers to adopt more stringent QC workflows. Consumer demand shifted toward personalized oncology panels, driving a 22 % YoY rise in custom oligo orders. Finally, a $120 million Series C round led by Bessemer Venture Partners enabled Nucleate Labs to double its clean‑room capacity in Singapore, positioning it for the next wave of gene‑editing contracts.

Analyst Overview

From my perspective, the Market attractiveness of the oligonucleotide synthesis market remains high due to sustained growth in RNA therapeutics, gene editing and diagnostic applications, driving a compound annual growth rate above 12% through 2032. Competitive intensity is moderate; a few large OEMs dominate scale‑up capacity while niche players differentiate through proprietary chemistries and micro‑fluidic platforms. The Long‑term outlook is robust, underpinned by expanding pipelines and increasing regulatory approvals, suggesting a stable revenue trajectory. The Innovation landscape is accelerating, with enzymatic synthesis, AI‑guided design and continuous‑flow reactors reshaping cost structures and time‑to‑market. Demand–supply balance currently tips toward demand in high‑purity, GMP‑grade segments, prompting capacity expansions and strategic partnerships. Key risk factors include raw‑material price volatility, intellectual‑property disputes and potential regulatory shifts concerning novel chemistries. Investors and OEMs are advised to prioritize flexible manufacturing footprints and secure diversified supply chains to mitigate these exposures. Furthermore, collaborations between academia and biotech firms are accelerating the translation of novel chemistries into commercial scale, reinforcing market resilience and shaping the oligonucleotide synthesis market outlook over the next decade.

11 items

1. Executive Summary

2. oligonucleotide synthesis Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global oligonucleotide synthesis Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global oligonucleotide synthesis Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Academic Research Institutes

6.1.2. Pharmaceutical and Biotechnology Companies

6.1.3. Diagnostic Laboratories

6.1.4. Others

6.2. Global oligonucleotide synthesis Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Custom Oligonucleotides

6.2.2. Pre-designed Oligonucleotides

6.3. Global oligonucleotide synthesis Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global oligonucleotide synthesis Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global oligonucleotide synthesis Market by: Regions (Value)

8. Global oligonucleotide synthesis Market Competition by Key Manufacturers

8.1. Global oligonucleotide synthesis Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global oligonucleotide synthesis: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Integrated DNA Technologies

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Merck (Merck)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eurofins Genomics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific (Thermo Fisher Scientific)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Agilent Technologies (Agilent Technologies)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Eurogentec

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. GE Healthcare (GE Healthcare)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. LGC Biosearch Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Nitto Denko Avecia

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Genscript (Genscript)

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Genedesign

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. TriLink Biotechnologies

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Bio-Synthesis

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. ATDBio

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global oligonucleotide synthesis Market

Figure 4: Global oligonucleotide synthesis Market: Drivers

Figure 5: Global oligonucleotide synthesis Market: Challenges

Figure 6: Global oligonucleotide synthesis Market: Trends

Figure 7: Global oligonucleotide synthesis Market: Opportunity

Figure 8: Global oligonucleotide synthesis Market: Restraint

Figure 9: Global oligonucleotide synthesis Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global oligonucleotide synthesis Market Value (USD Million) By Region

Figure 15: Global oligonucleotide synthesis Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global oligonucleotide synthesis Market Value (USD Million) By Region

Figure 23: Global oligonucleotide synthesis Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global oligonucleotide synthesis Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global oligonucleotide synthesis Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global oligonucleotide synthesis Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global oligonucleotide synthesis Market Value (USD Million) By Region

Table 10: Global oligonucleotide synthesis Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global oligonucleotide synthesis Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global oligonucleotide synthesis Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global oligonucleotide synthesis Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Integrated DNA Technologies Basic Information And Sales Area

Table 31: Integrated DNA Technologies. Products Portfolio

Table 32: Merck (Merck) Basic Information And Sales Area

Table 33: Merck (Merck). Products Portfolio

Table 34: Eurofins Genomics Basic Information And Sales Area

Table 35: Eurofins Genomics. Products Portfolio

Table 36: Thermo Fisher Scientific (Thermo Fisher Scientific) Basic Information And Sales Area

Table 37: Thermo Fisher Scientific (Thermo Fisher Scientific). Products Portfolio

Table 38: Agilent Technologies (Agilent Technologies) Basic Information And Sales Area

Table 39: Agilent Technologies (Agilent Technologies). Products Portfolio

Table 40: Eurogentec Basic Information And Sales Area

Table 41: Eurogentec. Products Portfolio

Table 42: GE Healthcare (GE Healthcare) Basic Information And Sales Area

Table 43: GE Healthcare (GE Healthcare). Products Portfolio

Table 44: LGC Biosearch Technologies Basic Information And Sales Area

Table 45: LGC Biosearch Technologies. Products Portfolio

Table 46: Nitto Denko Avecia Basic Information And Sales Area

Table 47: Nitto Denko Avecia. Products Portfolio

Table 48: Genscript (Genscript) Basic Information And Sales Area

Table 49: Genscript (Genscript). Products Portfolio

Table 50: Genedesign Basic Information And Sales Area

Table 51: Genedesign. Products Portfolio

Table 52: TriLink Biotechnologies Basic Information And Sales Area

Table 53: TriLink Biotechnologies. Products Portfolio

Table 54: Bio-Synthesis Basic Information And Sales Area

Table 55: Bio-Synthesis. Products Portfolio

Table 56: ATDBio Basic Information And Sales Area

Table 57: ATDBio. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global oligonucleotide synthesis Market Value (USD Million) By Region

Table 63: Global oligonucleotide synthesis Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current oligonucleotide synthesis market size?

The oligonucleotide synthesis market size was roughly USD 1.2 billion in 2023, reflecting strong demand from therapeutic, diagnostic and research applications. This figure consolidates revenues from custom synthesis services, automated platforms, and specialty reagents worldwide across.

2. What is the projected growth rate and forecast through 2032?

Analysts project the oligonucleotide synthesis market to expand at a compound annual growth rate of about 5.8 % between 2024 and 2032, reaching roughly USD 2.1 billion by the end of the forecast period. Growth is driven by expanding therapeutic pipelines and increased adoption of nucleic‑acid‑based diagnostics.

3. Which factors are the primary drivers behind market expansion?

Key drivers include the surge in personalized medicine, rising approvals of antisense and siRNA drugs, broader use of CRISPR‑based therapies, and growing demand for high‑throughput sequencing kits. Additionally, biotech outsourcing trends and cost‑effective automated synthesizers boost overall market momentum.

4. What challenges could impede market growth?

The market faces challenges such as high manufacturing costs for long oligonucleotides, stringent purity requirements, limited raw‑material supply chains, and intellectual‑property disputes. Moreover, regulatory uncertainty for emerging gene‑editing products and competition from alternative synthesis technologies may restrain expansion.

5. Which regions lead the oligonucleotide synthesis market today?

North America remains the dominant region, driven by extensive R&D spending and a concentration of biotech hubs in the United States. Europe follows closely, especially the United Kingdom and Germany, while Asia‑Pacific shows the fastest growth, propelled by China’s expanding biotech sector.

6. Who are the top companies competing in this space?

Leading players include Thermo Fisher Scientific, Integrated DNA Technologies, Merck KGaA (MilliporeSigma), Agilent Technologies, and Biosearch Technologies. These firms differentiate through proprietary chemistries, scale‑up capabilities, and integrated service platforms that cater to both custom synthesis and high‑volume reagent supply.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in long‑chain oligonucleotides for gene‑editing, conjugated delivery platforms, and AI‑driven synthesis optimization. Additionally, partnerships with pharmaceutical giants to co‑develop nucleic‑acid therapeutics and expansion into point‑of‑care diagnostic kits present lucrative growth avenues.

8. How are emerging technologies reshaping synthesis processes?

Automation, microfluidic reactors, and enzymatic synthesis are transforming traditional phosphoramidite chemistry, reducing cycle times and waste. Machine‑learning models now predict coupling efficiencies, enabling real‑time process adjustments and higher yields, which lower costs and improve scalability for large‑volume production.

9. What regulatory considerations affect market participants?

Regulatory frameworks vary globally; in the U.S., FDA’s cGMP guidelines govern therapeutic oligonucleotide production, while Europe follows EMA’s Annex 1 requirements. Compliance with ICH Q7 for active pharmaceutical ingredients and emerging gene‑therapy regulations adds complexity to product launch timelines.

Contact for Full Report

Loading report content...

Why Is the oligonucleotide synthesis Market Growing So Fast? 2026 Analysis

Market Snapshot

oligonucleotide synthesis Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

oligonucleotide synthesis Segmentation

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current oligonucleotide synthesis market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are the primary drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions lead the oligonucleotide synthesis market today?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How are emerging technologies reshaping synthesis processes?

9. What regulatory considerations affect market participants?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

oligonucleotide synthesis Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

oligonucleotide synthesis Segmentation

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current oligonucleotide synthesis market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are the primary drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions lead the oligonucleotide synthesis market today?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How are emerging technologies reshaping synthesis processes?

9. What regulatory considerations affect market participants?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation